Login to Your Account

GTx Starts Phase III Study With Prostate Cancer Drug

By Randall Osborne

Tuesday, November 11, 2003
With its initial public offering yet to price, GTx Inc. said it began a Phase III study with Acapodene (toremifene citrate) tablets for reducing skeletal fractures and other complications of androgen deprivation therapy in men with prostate cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription